Evidence map›Paper›PMID 42174661›Full record

ReviewMolecular cancer2026

Beyond Darwin: reactive heredity, burst-drift dynamics and eco‑evolutionary control of cancer.

Laurine Lagache, Julien Salzet, Isabelle Fournier, Michel Salzet

Abstract readReview
In one paragraph

Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Laurine LagacheUniv. Lille, Inserm, CHU Lille, U1192, Protéomique Réponse Inflammatoire Spectrométrie de Masse (PRISM), Lille, F-59000, France.
Julien SalzetUniv. Lille, Inserm, CHU Lille, U1192, Protéomique Réponse Inflammatoire Spectrométrie de Masse (PRISM), Lille, F-59000, France.
Isabelle FournierUniv. Lille, Inserm, CHU Lille, U1192, Protéomique Réponse Inflammatoire Spectrométrie de Masse (PRISM), Lille, F-59000, France.
Michel SalzetUniv. Lille, Inserm, CHU Lille, U1192, Protéomique Réponse Inflammatoire Spectrométrie de Masse (PRISM), Lille, F-59000, France. michel.salzet@univ-lille.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Darwinian clonal evolution provides a necessary framework for understanding tumour progression, yet emerging evidence shows that some cancers depart from a strictly gradualist tempo through episodic "macroevolutionary" leaps. We propose a unifying Burst-Drift-Control (BDC) model in which short-lived genomic reconfigurations ("bursts") that transiently alter heritable genomic states ("reactive heredity") precede longer intervals of constrained expansion, creating time-bounded vulnerabilities that clinicians may strategically steer ("control"). In this usage, the Drift component refers specifically to a drift-dominated or weak-selection interval after any initial post-burst sorting, not to the selective sweep itself. In the Burst phase, single catastrophic events, such as extrachromosomal DNA amplifications, chromothripsis, chromoplexy or whole-genome doubling, can generate major shifts in genotype and phenotype. These bursts produce new genetic configurations and can increase evolvability, for example when ecDNA circles permit oncogene dose tuning and non-Mendelian inheritance. During the drift-dominated interval, tumours may enter longer periods of constrained or near-neutral expansion in which spatial structure, clonal interference and weak or unresolved selection allow multiple lineages to persist, although the prevalence of such dynamics varies substantially by tumour type and treatment context. BDC does not assume that selective advantage is higher immediately after a burst than at later time points; later therapy or microenvironmental change can also impose strong selection. Finally, in the Control phase, if therapy is timed to exploit ecological dependencies and the fitness costs of resistance, cancer growth may be restrained as a stable, polyclonal "oligopoly" rather than progressing rapidly to an aggressive monoclonal takeover. We discuss supporting evidence, counterexamples and practical limitations, and argue that the main value of BDC lies in linking punctuated genome change to testable windows for evolutionary steering.

Indexed as

Clonal EvolutionEvolution, MolecularGenetic DriftNeoplasmsAnimalsHumansModels, GeneticSelection, GeneticAdaptive therapyCancer evolutionChromothripsisDrift-dominated intervalEco-evolutionary tumour dynamicsExtrachromosomal DNA (ecDNA)Punctuated copy-number evolutionWhole-genome doubling

Identifiers

PMID42174661
PMCPMC13374208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.